BridgeBio Pharma, Inc. (BBIO) Latest Company News

Aug 31, 2026, 19:14 UTC
President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.
Source:
Aug 28, 2026, 09:23 UTC
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.
Source:
Aug 26, 2026, 11:30 UTC
BridgeBio announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM.
Source:
- globenewswire.com
Aug 24, 2026, 11:30 UTC
BridgeBio Pharma announced that new acoramidis data from open-label extension analyses in ATTR-CM will be presented at the ESC Congress 2026 in Munich, Germany, on August 28-31, 2026.
Source:
- globenewswire.com
Aug 14, 2026, 00:35 UTC
KKR affiliate is selling BridgeBio Pharma shares at $78-$80 per share, as reported on August 13, 2026.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 13, 2026, 21:42 UTC
BridgeBio Pharma announced the launch of a secondary public offering of 5,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P.; BridgeBio will not receive any proceeds.
Source:
- globenewswire.com
- globenewswire.com
Aug 10, 2026, 22:04 UTC
BridgeBio Pharma reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026.
Source:
Jul 22, 2026, 11:30 UTC
BridgeBio Pharma announced that the FDA accepted for filing its New Drug Application for encaleret for the treatment of autosomal dominant hypocalcemia type 1.
Source:
- globenewswire.com
Jul 1, 2026, 11:30 UTC
BridgeBio Pharma raised $1 billion in preferred equity financing led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, at an initial conversion price of approximately $138 per share.
Source:
Jun 26, 2026, 00:00 UTC
BridgeBio Pharma announced the departure of director Randal W. Scott and the election of directors James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine, effective June 22, 2026.

BBIO

President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.

AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.

BridgeBio announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM.

BridgeBio Pharma announced that new acoramidis data from open-label extension analyses in ATTR-CM will be presented at the ESC Congress 2026 in Munich, Germany, on August 28-31, 2026.

KKR affiliate is selling BridgeBio Pharma shares at $78-$80 per share, as reported on August 13, 2026.

BridgeBio Pharma announced the launch of a secondary public offering of 5,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P.; BridgeBio will not receive any proceeds.

BridgeBio Pharma reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026.

BridgeBio Pharma announced that the FDA accepted for filing its New Drug Application for encaleret for the treatment of autosomal dominant hypocalcemia type 1.

BridgeBio Pharma raised $1 billion in preferred equity financing led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, at an initial conversion price of approximately $138 per share.

BridgeBio Pharma announced the departure of director Randal W. Scott and the election of directors James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine, effective June 22, 2026.